Aquestive Therapeutics Files Proxy Statement for 2025 Annual Meeting

Ticker: AQST · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1398733

Aquestive Therapeutics, Inc. DEF 14A Filing Summary
FieldDetail
CompanyAquestive Therapeutics, Inc. (AQST)
Form TypeDEF 14A
Filed DateApr 25, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, annual-meeting, regulatory-filing

Related Tickers: AQST

TL;DR

AQST proxy filed - shareholders vote on company matters at June 11 meeting.

AI Summary

Aquestive Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 25, 2025, for its annual meeting on June 11, 2025. The filing concerns the solicitation of proxies from shareholders regarding matters to be voted on at the meeting. The company, previously known as MonoSol Rx, Inc., is based in Warren, NJ.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda for the annual meeting, including any proposals or director elections, allowing them to make informed voting decisions.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders and does not inherently introduce new financial risks.

Key Players & Entities

  • Aquestive Therapeutics, Inc. (company) — Registrant
  • MonoSol Rx, Inc. (company) — Former company name
  • 20250425 (date) — Filing date
  • 20250611 (date) — Meeting date

FAQ

What is the purpose of this DEF 14A filing?

The purpose of the DEF 14A filing is to solicit proxies from shareholders for the upcoming annual meeting of Aquestive Therapeutics, Inc.

When is the Aquestive Therapeutics, Inc. annual meeting scheduled?

The annual meeting is scheduled for June 11, 2025.

What is the filing date of this proxy statement?

This definitive proxy statement was filed on April 25, 2025.

What was Aquestive Therapeutics, Inc.'s former name?

Aquestive Therapeutics, Inc.'s former name was MonoSol Rx, Inc.

Where is Aquestive Therapeutics, Inc. headquartered?

Aquestive Therapeutics, Inc. is headquartered at 30 Technology Drive, Warren, NJ 07059.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Aquestive Therapeutics, Inc. (AQST).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.